Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Bernard, Xavier ^a   Robinson, Philip ^b   Nominé, Yves ^a   Masson, Murielle ^a   Charbonnier, Sebastian ^a   Ramirez Ramos, Juan Ramon ^a   Deryckere, Francois ^a   Travé, Gilles ^a   Orfanoudakis, Georges ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; GLYCINE; LEUCINE; PROTEASOME; PROTEIN E6; PROTEIN MDM2; PROTEIN P53; THREONINE; TYROSINE; VALINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; MDM2 PROTEIN, HUMAN; ONCOPROTEIN; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MUTANT; NONHUMAN; NUCLEOTIDE BINDING SITE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; RABBIT; RETICULOCYTE; TRANSACTIVATION; WART VIRUS; BINDING SITE; CHEMISTRY; GENETICS; METABOLISM; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS;

HUMAN PAPILLOMAVIRUS;

BINDING SITES; HUMANS; MUTAGENESIS, SITE-DIRECTED; ONCOGENE PROTEINS, VIRAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80055034154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025981     Document Type: Article

References (55)

1. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, et al. (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
2. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak, et al. (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781.
3. May P, May E, (1999) Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621-7636.
4. Bode AM, Dong Z, (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
5. Cho Y, Gorina S, Jeffrey PD, Pavletich NP, (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW, (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311.
7. Maki CG, Huibregtse JM, Howley PM, (1996) In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 56: 2649-2654.
8. Brooks CL, Gu W, (2004) Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle 3: 895-899.
9. Yu ZK, Geyer RK, Maki CG, (2000) MDM2-dependent ubiquitination of nuclear and cytoplasmic p53. Oncogene 19: 5892-5897.
10. Haupt Y, Maya R, Kazaz A, Oren M, (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
11. Whibley C, Pharoah PD, Hollstein M, (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
12. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, et al. (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20: 4041-4049.
13. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, et al. (1993) p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234.
14. Momand J, Zambetti GP, Olson DC, George D, Levine AJ, (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
15. Soria C, Estermann FE, Espantman KC, O'Shea CC, (2010) Heterochromatin silencing of p53 target genes by a small viral protein. Nature 466: 1076-1081.
16. Dobner T, Horikoshi N, Rubenwolf S, Shenk T, (1996) Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272: 1470-1473.
17. Grand RJ, Parkhill J, Szestak T, Rookes SM, Roberts S, et al. (1999) Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein. Oncogene 18: 955-965.
18. Huibregtse JM, Scheffner M, Howley PM, (1993) Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13: 775-784.
19. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
20. Werness BA, Levine AJ, Howley PM, (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79.
21. Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, et al. (2006) Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665-678.
22. Barbosa MS, Schlegel R, (1989) The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 4: 1529-1532.
23. Grossman SR, Mora R, Laimins LA, (1989) Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol 63: 366-374.
24. Schwarz SE, Rosa JL, Scheffner M, (1998) Characterization of human hect domain family members and their interaction with UbcH5 and UbcH7. J Biol Chem 273: 12148-12154.
25. Talis AL, Huibregtse JM, Howley PM, (1998) The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 273: 6439-6445.
26. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM, (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
27. Liu Y, Kim BO, Kao C, Jung C, Dalton JT, et al. (2004) Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem 279: 21766-21773.
28. Be X, Hong Y, Wei J, Androphy EJ, Chen JJ, et al. (2001) Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 40: 1293-1299.
29. Gu J, Rubin RM, Yuan ZM, (2001) A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. Oncogene 20: 3519-3527.
30. Li X, Coffino P, (1996) Identification of a region of p53 that confers lability. J Biol Chem 271: 4447-4451.
31. Li X, Coffino P, (1996) High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70: 4509-4516.
32. Lechner MS, Laimins LA, (1994) Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68: 4262-4273.
33. Thomas M, Massimi P, Jenkins J, Banks L, (1995) HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 10: 261-268.
34. Mansur CP, Marcus B, Dalal S, Androphy EJ, (1995) The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10: 457-465.
35. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, et al. (2002) The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277: 28446-28458.
36. Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, et al. (2006) The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A 103: 1227-1232.
37. Bech-Otschir D, Kraft R, Huang X, Henklein P, Kapelari B, et al. (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. Embo J 20: 1630-1639.
38. Stewart D, Kazemi S, Li S, Massimi P, Banks L, Koromilas AE, et al. (2004) Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. J Gen Virol 85: 1419-1426.
39. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
40. Picksley SM, Vojtesek B, Sparks A, Lane DP, (1994) Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529.
41. Gu J, Chen D, Rosenblum J, Rubin RM, Yuan ZM, (2000) Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. Mol Cell Biol 20: 1243-1253.
42. Pavletich NP, Chambers KA, Pabo CO, (1993) The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7: 2556-2564.
43. Wang PL, Sait F, Winter G, (2001) The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. Oncogene 20: 2318-2324.
44. Stephen CW, Lane DP, (1992) Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol 225: 577-583.
45. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, et al. (1999) Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A 96: 8438-8442.
46. Rudiger S, Freund SM, Veprintsev DB, Fersht AR, (2002) CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci U S A 99: 11085-11090.
47. Bullock AN, Fersht AR, (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1: 68-76.
48. Olsson A, Manzl C, Strasser A, Villunger A, (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14: 1561-1575.
49. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, et al. (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278: 37536-37544.
50. Burch LR, Midgley CA, Currie RA, Lane DP, Hupp TR, (2000) Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett 472: 93-98.
51. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL, (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23: 251-263.
52. Baker S J, Markowitz S, Fearon ER, Willson JK, Vogelstein B, (1990) Suppression of humain colorectal carcinoma cell growth by wild-type p53. Science 24: 912-915.
53. Giovane C, Trave G, Briones A, Lutz Y, Wasylyk B, et al. (1999) Targetting of the N-terminal domain of the humain papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53. J Mol Recognit 2: 141-152.
54. Haupt Y, Barak Y, Oren M, (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. Embo J 15: 1596-1606.
55. Schanda P, Kupce E, Brutscher B, (2005) SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds. J Biomol NMR 33: 199-211.